Melissa Rewolinski
Director/Board Member en ARBUTUS BIOPHARMA CORPORATION .
Fortuna: 583 $ al 31/05/2023
Perfil
Melissa V.
Rewolinski is the founder of Mvr Consulting, Inc. (founded in 2018) where she holds the title of Principal.
She is currently the Director at American Type Culture Collection since 2021 and Independent Director at Arbutus Biopharma Corp.
since 2023.
Dr. Rewolinski previously served as an Independent Director at Lannett Co., Inc. from 2019 to 2023, Senior Director-Development at Amira Pharmaceuticals, Inc. from 2006 to 2008, and Senior Vice President & Head-Technical Operations at Intercept Pharmaceuticals, Inc. from 2008 to 2018.
She obtained her undergraduate and doctorate degrees from Rice University in 1991 and 1995, respectively.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LANNETT COMPANY, INC.
0.22% | 31/10/2022 | 23 315 ( 0.22% ) | 583 $ | 31/05/2023 |
Cargos activos de Melissa Rewolinski
| Empresas | Cargo | Inicio |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 12/07/2023 |
| Mvr Consulting, Inc. | Founder | 01/08/2018 |
American Type Culture Collection
 American Type Culture Collection BiotechnologyHealth Technology American Type Culture Collection operates as a global biological materials resource and standards organization offering a collection of products and services. Its services include production and characterization, testing, biorepository, and deposit. The company was founded in 1925 and is headquartered in Manassas, VA. | Director/Board Member | 01/09/2021 |
Antiguos cargos conocidos de Melissa Rewolinski.
| Empresas | Cargo | Fin |
|---|---|---|
| LANNETT COMPANY, INC. | Director/Board Member | 16/06/2023 |
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2018 |
Amira Pharmaceuticals, Inc.
 Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Corporate Officer/Principal | 01/04/2008 |
Formación de Melissa Rewolinski.
| Rice University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| LANNETT COMPANY, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Empresas privadas | 3 |
|---|---|
Amira Pharmaceuticals, Inc.
Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Health Technology |
American Type Culture Collection
American Type Culture Collection BiotechnologyHealth Technology American Type Culture Collection operates as a global biological materials resource and standards organization offering a collection of products and services. Its services include production and characterization, testing, biorepository, and deposit. The company was founded in 1925 and is headquartered in Manassas, VA. | Health Technology |
| Mvr Consulting, Inc. |
- Bolsa de valores
- Insiders
- Melissa Rewolinski
